CytoMed Therapeutics (GDTC) EBITDA (2020 - 2025)
CytoMed Therapeutics (GDTC) EBITDA from Mar 31, 2020 to Dec 31, 2025. The TTM CytoMed Therapeutics (GDTC) EBITDA is -$4.08M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
CytoMed Therapeutics (GDTC) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +132.29% |
| 3 Years TTM | +29.30% |
| 5 Years TTM | +40.44% |
| All Time TTM | +39.57% |
Annual EBITDA change of CytoMed Therapeutics (GDTC)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$3.35M | +87.11% |
| 2024 | -$1.79M | -39.38% |
| 2023 | -$2.95M | +168.78% |
| 2022 | -$1.10M | +4.17% |
| 2021 | -$1.05M | +35.05% |
| 2020 | -$780K | +123.31% |
| 2019 | -$349K | N/A |